Top Trump Administration Official Abruptly Resigns - White House Responds After FDA's Makary Steps Aside
WASHINGTON, D.C. — FDA Commissioner Marty Makary resigned Tuesday, ending his tenure at the agency amid internal discussions about the direction of health policy initiatives. A White House official described the departure as related to “process at the FDA” rather than any single issue, and stated there was “no bad blood” between President Donald Trump and Makary. Health and Human Services Secretary Robert F. Kennedy Jr. reportedly encouraged the resignation as dissatisfaction with the agency’s pace on certain priorities grew.
Kyle Diamantas, the FDA’s deputy commissioner for food, will serve as acting commissioner. A White House spokesperson noted that Diamantas had previously removed himself from a legal case involving Planned Parenthood due to personal convictions. President Trump publicly praised Makary, calling him a “great doctor” and a hard worker who was respected by all. Trump posted on Truth Social thanking Makary for his service and confirming that Diamantas would take the acting role.
Kennedy also offered positive remarks about Makary’s contributions, stating that he had challenged entrenched interests and advanced reforms under the “Make America Healthy Again” mission. Kennedy added that the search for a permanent replacement is already underway.
Makary’s resignation follows criticism from some pro-life advocates who felt the administration had not moved quickly enough on policies related to the abortion pill mifepristone, including restrictions on telehealth prescriptions and mail distribution. Live Action President Lila Rose had publicly called for Makary’s removal. Republican Sen. Josh Hawley welcomed the resignation, describing Makary as “terrible to the pro-life movement” and noting opportunities for the FDA to reset its approach.
May you like
Makary had been scheduled to testify before the Senate Appropriations Committee on Wednesday. His exit marks another personnel change within the Trump administration as it continues to reshape federal health agencies. No specific reason was given for the timing of the resignation beyond the White House’s statement on process concerns. The FDA has not issued a formal statement on the leadership transition.
The developments reflect ongoing discussions within the administration about the pace and direction of health policy reforms. Observers note that the FDA plays a central role in regulating drugs, medical devices, and food safety, and leadership transitions can influence regulatory priorities. The agency continues to operate under existing leadership structures while a permanent commissioner is selected. The situation remains fluid as the administration evaluates next steps for the FDA.
